3D Medicines Inc.

Chinese drug makers have made both major cuts and additions to their R&D pipelines in recent months, including for antibody-drug conjugates (ADCs) amid increasingly fierce competition, a Scrip revie

Wrapping up a challenging 2023, Chinese pharma firms increasingly ventured into the US to initiate Phase III clinical trials to support future regulatory approvals from the US Food and Drug Administra

The UK MHRA has become the first regulator in the world to approve for marketing a subcutaneous (SC) version of Roche ’s anti-PD-(L)1 cancer immunotherapy, Tecentriq (atezolizumab), which cuts treatm

China’s Center for Drug Evaluation (CDE) has expounded its views on four major issues that have arisen from assessing novel antitumor drug candidates under the country's conditional approval scheme, t